期刊文献+

Fabp4在3种病理性妊娠患者胎盘组织中的表达及意义 被引量:3

Expression and significance of Fabp4 in FGR PIH GDM women′s placenta
暂未订购
导出
摘要 目的探讨脂肪酸结合蛋白(Fabp4)基因及其蛋白在胎儿生长受限(FGR)、妊娠期糖尿病(GDM)、妊娠期高血压疾病(PIH)这3种病理性妊娠患者胎盘组织中的表达及意义。方法采用免疫组织化学的方法检测Fabp4蛋白在3种病理性妊娠患者胎盘组织中的表达差异,采用荧光实施定量PCR的方法对Fabp4的mRNA在3种病理性妊娠患者胎盘组织中的表达进行相关性分析。结果免疫细胞化学检测发现在这3种病理性妊娠患者的胎盘中,Fabp4的蛋白表达明显高于正常组的胎盘。而通过实时定量检测发现Fabp4的mRNA表达水平在3种病理性妊娠患者胎盘中也高于正常组,其中胎儿生长受限组的mRNA表达水平明显高于正常组,差异具有统计学意义(P<0.05)。结论 Fabp4蛋白和mRNA在FGR、GDM、PIH这3种病理性妊娠患者胎盘中的表达均升高,提示Fabp4可能与这3种病理性妊娠有重要关系。 Objective To elucidate the expression and significance of Fabp4 in the placenta of Fetal growth restriction(FGR),Gestational diabetes mellitus(GDM) and Hypertensive disorders in pregnancy(PIH).Methods The difference of protein of Fabp4 detected by immunohistochemically and analysis the differently expression of Fabp4 mRNA using the method of real-time PCR in the placenta of FGR,PIH and GDM.Results The expression of protein and Fabp4 mRNA in the placenta of FGR,PIH and GDM were higher than that in normal,especially the disparity in the placenta of FGR was obvious,having the statistical significance.Conclusion The higher expression of protein and mRNA of Fabp4 in the placenta of FGR,PIH and GDM suggest that Fabp4 has a relationship with FGR,GDM and PIH.
出处 《重庆医学》 CAS CSCD 北大核心 2010年第14期1801-1804,I0001,共5页 Chongqing medicine
基金 南京军区医药卫生重点科研项目(2007Z018) 厦门市社会发展科技项目(3502Z20074030)
关键词 胎盘 胎儿生长受限 妊娠期糖尿病 妊娠期高血压疾病 脂肪酸结合蛋白4 placenta fetal growth restriction Gestational diabetes mellitus hypertensive disorders in pregnancy fatty acid-binding protein
  • 相关文献

参考文献15

  • 1Chmurzynska A.The multigene family of fatty acid-binding proteins(FABPs):function,structure and polymorphism[J].J Appl Genet,2006,47:39.
  • 2Ayers SD,Nedrow KL,Gillilan RE,et al.Continuous nucleocytoplasmic shuttling underlies transcriptional activation of PPAR gamma by Fabp4[J].Biochemistry,2007,46:6744.
  • 3Doyle LW,Faber B,Callanan C,et al.Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence[J].Pediatrics,2006,118:108.
  • 4Arroyo JA,Winn VD.Vasculogenesis and angiogenesis in the IUGR placenta[J].Semin Perinatol,2008,32:172.
  • 5Hay WW.Placental-fetal glucose exchange and fetal glucose metabolism[J].Trans Am Clin Climatol Assoc,2006,117:321.
  • 6Haggarty P.Effect of placental function on fatty acid requirements during pregnancy[J].Eur J Clin Nutr,2004,58:1559.
  • 7Gauster M,Hiden U,Blaschitz A,et al.Dysregulation of placental endothelial lipase and lipoprotein lipase in intrauterine growth-restricted pregnancies[J].J Clin Endocrinol Metab,2007,92:2256.
  • 8杨慧霞.妊娠合并糖尿病临床诊断与治疗推荐指南(草案)[J].中国实用妇科与产科杂志,2007,23(6):475-477. 被引量:374
  • 9Koech A,Ndungu B,Gichangi P.Structural changes in umbilical vessels in pregnancy induced hypertension[J].Placenta,2008,29:210.
  • 10Furuhashi M,Fucho R,Gorgun CZ,et al.Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice[J].J Clin Invest,2008,118:2640.

二级参考文献16

  • 1Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest,2003,111:649-658.
  • 2Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor (sFlt-1) induces proteinuria. J Biol Chem,2003,278:12605-12608.
  • 3Vaillant P, David E, Constant I, et al. Validity in nulliparas of increased beta-human chorionic gonadotrophin at mid-term for predicting pregnancy-induced hypertension complicated with proteinuria and intrauterine growth retardation. Nephron,1996,72:557-
  • 4Smith GC, Stenhouse EJ, Crossley JA, et al. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia,and stillbirth. J Clin Endocrinol Metab, 2002, 87: 1762-1767.
  • 5Takemasa I, Higuchi H, Yamamoto H, et al. Construction of preferential cDNA microarray specialized for human colorectal carcinoma: molecular sketch of colorectal cancer. Biochem Biophys Res Commun, 2001, 285: 1244-1249.
  • 6Diatchenko L, Lau YF, Campell AP, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci,1996,93:6025-6030.
  • 7Bussolati B, Dunk C, Grohman M, et al. Vascualr endothelial growth factor receptor-1 modulates vascular endothelial growth factor mediated angiogenesis via nitric oxide. Am J Pathol,2001,159:993-1008.
  • 8Livingston JC, Chin R, Haddad B, et al. Reductions of vascular endothelial growth factor and placenta growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol,2000,183:1554-1557.
  • 9Sharkey AM, Charnock-Jones DS, Boocock CA, et al. Expre-ssion of mRNA for vascular endothelial growth factor in human placenta. J Reprod Fertil,1993,99:609-615.
  • 10Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci,1993,90:10705-10709.

共引文献379

同被引文献31

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部